Feb 18, 2011, 05.01 PM
Hyderabad-based biotechnology company Transgene Biotek plans to raise USD 40 million via global depositary receipt (GDR).
In an exclusive interview with CNBC-TV18's Ekta Batra and Reema Tendulkar, SS Marthi, Director of Transgene Biotek says, "The proposal is to raise USD 40 million via issuance of GDR. A part of this USD 40 million will be utilised for the present product line, which includes oncology drugs, active pharmaceutical ingredients (APIs), oral delivery platform of oral insulin, etc."
Going forward, the company is also looking at certain acquisitions, and, "the proceeds will be utilised for acquisitions as well," he adds.
The company is engaged in sales of medical diagnostic products and services.
Transgene Biote stock price
On April 29, 2016, Transgene Biotek closed at Rs 1.80, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 4.84 and the 52-week low was Rs 1.71.
The latest book value of the company is Rs 23.51 per share. At current value, the price-to-book value of the company was 0.08.
HeidelbergCement India has reported a sales turnov
Medi-Caps has reported a sales turnover of Rs 6.77
When you unplug you mind for a minute, you restore
Reliance Infra posted its third quarter results. N
Himalaya's Ravi Prasad talks about the contrarian
The continuous uptrend in Indian market is reflect